← All companies
$19.10
+3.30% (+$0.61) on the day
Close Nov 13, 2026
Market cap
$1.31B
1 month
+1.54%
52-week range
$12.04–$31.44
Last month
Why we cover it
Developing GH001, an inhaled form of 5-MeO-DMT, for treatment-resistant depression, after a positive Phase 2b trial. One of the best-funded pure-play psychedelic companies.
Financials
| Cash & equivalents | $246M | as of Dec 31, 2025 · 20-F |
| Research & development | $38.8M | year ended Dec 31, 2025 · 20-F |
| Net income (loss) | −$48.3M | year ended Dec 31, 2025 · 20-F |
From the company's SEC filings. See all filings ↗
Clinical trials Trials tracker
| Trial | Compound | Stage |
|---|---|---|
| GH001 for Treatment-Resistant Depression | 5-MeO-DMT | Phase 2b complete; Phase 3 planned |
News (4)
- Sep 28, 2026 A Second Dose of AtaiBeckley's 5-MeO-DMT Drug Also Beat Depression, Trial Data Shows
- Aug 24, 2026 New on Altitude: The 5-MeO-DMT Patent Race Has a Twist
- Jun 4, 2026 10 for 10: Every Patient in a Small Postpartum Depression Trial of Inhaled 5-MeO-DMT Went Into Remission
- Jan 5, 2026 FDA Clears the Way for a Global Phase 3 Trial of Inhaled 5-MeO-DMT
In the Journal (10)
- Sep 29, 2026 Only 3 of 10 Psychedelic Companies Lobby Washington. One Just Joined — Twice, in the Same Quarter.
- Sep 26, 2026 150+ Patents, $113 Million Raised, 4 Employees: Inside the Company Betting It Doesn't Need to Run Its Own Trials
- Sep 23, 2026 Which Psychedelic-Company CEO's Pay Actually Matched Their Stock's Performance? We Checked All 10 — Almost None Did.
- Sep 22, 2026 How Clinical Trials Actually Work — and What It Means for the Psychedelic Industry
- Sep 17, 2026 The Psychedelic Money Graveyard: Renames, Reverse Mergers, and the Companies That Didn't Make It
- Sep 11, 2026 The Psychedelic Money Rankings: $11 Billion Public, $1.6 Billion Private, $140 Million From Governments
- Aug 26, 2026 LSD Has 14 Patents in Our Tracker. The Company Closest to Approval Owns One.
- Aug 24, 2026 The 5-MeO-DMT Patent Race Has a Twist: The Clinical Leader Barely Owns Any of It
- Aug 17, 2026 677 Patents and One FDA Rejection: Mapping the Psychedelic Drug Pipeline
- Feb 14, 2026 The Clinical Revolution: Psilocybin and 5-MeO-DMT Move from Underground to Evidence-Based Medicine
Prices are end-of-day closes from Nasdaq; financials come from SEC filings. Not investment advice.